Filing Flows › Journey Medical (DERM) › Q2 2026
Journey Medical (DERM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Journey Medical (DERM) reported revenue of $18.5M for the second quarter 2026 (Q2 2026), +23% from a year earlier and +16% from the quarter before. Operating margin was 2.5%, net loss $312K (1.7% of revenue).
Journey Medical, Q2 2026: revenue $18.5M (+23% year over year), operating margin 2.5%, net loss $312K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.5M | +16% | +23% |
| Operating profit | $456K | — | — |
| Net earnings | −$312K | — | — |
| Operating cash flow | −$1.7M | -160% | — |
What changed
Revenue was $18.5M in Q2 2026, up 23% year over year and up 16% from the previous quarter. Emrosi was the largest line at 44% of revenue. Emrosi added $5.3M year over year (up 189%), 151% of the total change. Other / legacy declined 68%.
Operating profit was $456K, a 2.5% margin (up 21.6 points year over year). Total costs grew 1% against revenue growth of 23%. The fastest-growing cost line was Cost of revenue (+24%). The quarter ended with a net loss of $312K, narrower than the previous quarter's $2.2M loss. Net interest and other expense of $753K was the main reason.
Operating cash flow was −$1.7M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $2.9M.
Questions
What was Journey Medical's revenue in the second quarter 2026?
Journey Medical (DERM) reported revenue of $18.5M for the second quarter 2026 (Q2 2026), +23% from a year earlier and +16% from the quarter before.
Was Journey Medical profitable in the second quarter 2026?
Operating profit was $456K (2.5% of revenue) and net loss $312K.
Source: Journey Medical 10-Q on SEC EDGAR.